Bristol-Myers Embraces Anthropic’s AI for Enhanced Operations
Bristol-Myers Squibb is leveraging Anthropic's Claude AI to improve its research, drug development, and operational efficiency, marking a significant step in AI adoption within the biotech sector.
More from this archive
Alibaba Unveils Zhenwu M890 AI Chip, Boosting Domestic Tech Landscape
Alibaba's Zhenwu M890 AI chip promises significant performance improvements, offering a viable alternative to Nvidia's H200 in the…
OpenAI Seeks Community Engagement Lead Amid Data Center Controversy
OpenAI is on a mission to improve relations with communities affected by its planned data centers, offering a…
HKD2.2 Billion Southbound Trading Inflow Highlights Market Interest in SMIC
A notable HKD2.2 billion net inflow into SMIC reflects growing investor confidence in the semiconductor market, alongside substantial…
Karpathy Joins Anthropic Amid Turbulent AI Landscape
Andrej Karpathy's move to Anthropic highlights the ongoing talent shifts in AI, while regulatory developments and geopolitical tensions…
The archive
sorted by latestBristol Myers Squibb Partners with Anthropic for AI Integration
GPUBeat Desk · 2 min
Anthropic’s IPO Strategy Raises Alarm for Pre-IPO Investors
GPUBeat Desk · 3 min
SMIC Sees HKD2.7B Inflow Amid Stable Trading Activity
GPUBeat Desk · 2 min
AI Coding Agents Propel Rust Development to New Heights
GPUBeat Desk · 2 min
Southbound Capital Sees Surge in Hong Kong Stock Purchases
GPUBeat Desk · 2 min